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Abstract
A wide range of cancer immunotherapy approaches has been developed including non-specific immune-stimulants
such as cytokines, cancer vaccines, immune checkpoint inhibitors (ICIs), and adoptive T cell therapy. Among them,
ICIs are the most commonly used and intensively studied. Since 2011, these drugs have received marketing
authorisation for melanoma, lung, bladder, renal, and head and neck cancers, with remarkable and long-lasting
treatment response in some patients. The novel mechanism of action of ICIs, with immune and T cell activation,
leads to unusual patterns of response on imaging, with the advent of so-called pseudoprogression being more
pronounced and frequently observed when compared to other anticancer therapies. Pseudoprogression, described
in about 2–10% of patients treated with ICIs, corresponds to an increase of tumour burden and/or the appearance
of new lesions due to infiltration by activated T cells before the disease responds to therapy. To overcome the
limitation of response evaluation criteria in solid tumors (RECIST) to assess these specific changes, new imaging
criteria—so-called immune-related response criteria and then immune-related RECIST (irRECIST)—were proposed.
The major modification involved the inclusion of the measurements of new target lesions into disease assessments
and the need for a 4-week re-assessment to confirm or not confirm progression. The RECIST working group
introduced the new concept of “unconfirmed progression”, into the irRECIST. This paper reviews current
immunotherapeutic approaches and summarises radiologic criteria to evaluate new patterns of response to
immunotherapy. Furthermore, imaging features of immunotherapy-related adverse events and available predictive
biomarkers of response are presented.
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Key points
 Immune checkpoint inhibitors remove inhibitory
signals of T cell activation
 Pseudoprogression occurs in 2–10% of patients
treated with immunotherapy
 An increase of tumour burden during immune
checkpoint inhibitor treatment is more likely to
reflect true progression than pseudo-progression
 New criteria to assess immunotherapy are based on
two major assumptions: new lesions do not preclude
a progressive disease and a progression need to be
confirmed on 4–8 weeks follow-up imaging
 The knowledge of immune-related adverse events is
of utmost importance and requires the exclusion of
differentials, mainly of infectious or tumour nature
Background
Cancer immune surveillance plays an important role in
the origin and pathogenesis of cancer. Three essential
phases, i.e., elimination, equilibrium, and escape, appear to
contribute to tumourigenesis and tumour progression [1].
This dynamic crosstalk between tumour and immune sys-
tem is crucial. Over recent years, the identification of key
players of this interaction has led to an immense break-
through in cancer therapeutics with development of new
anticancer drugs targeting the immune system instead of
the tumour cells.
Patterns of disease response, stability, and progression
to immunotherapy may differ from those observed with
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
* Correspondence: Clarisse.dromain@chuv.ch
1Department of Radiology and Interventional Radiology, Lausanne University
Hospital and University of Lausanne, Rue du Bugnon 46, CH-1011 Lausanne,
Switzerland
Full list of author information is available at the end of the article
European Radiology
Experimental
Dromain et al. European Radiology Experimental             (2020) 4:2 
https://doi.org/10.1186/s41747-019-0134-1
other drugs, such as chemotherapies and targeted ther-
apies. Indeed, some patients experience a response after
an initial progression, so-called pseudoprogression, that
has led to the development of immune-specific related
response criteria where treatment may be used beyond a
progression evaluated according to the “response evalu-
ation criteria in solid tumors” (RECIST) criteria [2].
Although immune-checkpoint inhibitors (ICIs) are
safer compared to cytotoxic chemotherapy, various spe-
cific immunotherapy-related adverse events (irAEs) can
be often detected on imaging, even before the onset of
symptoms. Their prompt identification, systematically
requiring to exclude differentials, is crucial to allow an
optimal management.
In this paper, we aim to review the different approaches
of immunotherapy and the specific patterns of disease re-
sponse and progression to these new drugs, especially to
ICIs. Then, we describe the new criteria developed to as-
sess response to immunotherapy and discuss the major
immune-related side effects.
Different immunotherapy approaches
There are different types of immunotherapy (Fig. 1). Some
of these are non-specific immunotherapy, such as ICIs,
leading to a general stimulation of the immune system,
whereas others are more tumour-specific. Tumour-specific
immunotherapy is based on the recognition by immune
cells of unique tumour-specific antigens and includes differ-
ent types of therapeutic approaches such as oncolytic virus,
cancer vaccines, and adoptive cell transfer. Among these
emerging approaches of immunotherapy, the ICIs—anti-
programmed cell death protein 1 (PD-1), anti-programmed
cell death protein ligand 1 (PD-L1), and anti-cytotoxic T-
lymphocyte antigen (CTLA4)—are the most thoroughly in-
vestigated class of immunotherapy and increasingly used in
routine clinical practice.
Oncolytic viruses
The oncolytic viruses hold great promise in the fight
against cancer since it is designed to work by selective rep-
lication in cancer cells and to cause their death through
several mechanisms including promotion of cellular im-
munity and hijacking of cellular death pathways [3].
Several types of parental viruses are used including
herpes simplex virus type 1 and adenoviruses. Talimo-
gene laherparepvec (Imlygic™) consists of an engineered,
genetically modified herpes simplex virus type 1. It can
infect and selectively destroy malignant cells while acti-
vating the immune system by the coding sequence of the
granulocyte-macrophage colony-stimulating factor for
immunostimulation. This virus demonstrated to be
immunogenic and safe for the local treatment of unre-
sectable cutaneous, subcutaneous, and nodal lesions in
patients with recurrent melanoma after primary surgery.
It is currently approved for this indication in several
countries and was approved by the US Food and Drug
Administration (FDA) and the European Medicines
Agency [4, 5].
Approximately half of the patients had symptoms of fa-
tigue and chills/fever during the treatment, and roughly a
third of them had flu-like symptoms and nausea. There
were also some rare but serious side effects including cel-
lulitis, vitiligo, deep vein thrombosis, vasculitis, herpes
virus infection, and herpes simplex keratitis [4]. Several
clinical trials evaluating the intratumoural injection of tali-
mogene laherparepvec or other oncolytic viruses (e.g.,
intrahepatic, intrapancreatic, intraprostatic, or into breast
lesions) alone or in combination with ICIs are ongoing.
Cancer vaccines
T cells are characterised by the expression of T cell re-
ceptors capable of recognising intracellular antigenic
peptides uniquely expressed on the surface of major
histocompatibility complex molecules. The recognition
Fig. 1 Different approaches of immunotherapy. CAR Chimeric antigen receptor, DNA Deoxyribonucleic acid, TILs Tumour-infiltrating lymphocytes,
T-VEC Talimogene laherparepvec
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of foreign antigens such as viral proteins or altered anti-
gens such as the products of mutated cancer genes by T
cell receptors leads to their activation.
Currently, many diverse therapeutic vaccination strat-
egies are being developed or evaluated in clinical trials
including cell vaccines (autologous or allogeneic tumour
or immune cell), protein/peptide vaccines, and genetic—
deoxyribonucleic acid (DNA), ribonucleic acid (RNA),
and viral—vaccines depending on the sources of the an-
tigens [6]. A promising approach is the use of the most
potent antigen-presenting cells, the so-called circulating
dendritic cells, based on their capacity to initiate and
directly modulate specific immune responses [7].
In this context, naturally circulating dendritic cells are
isolated by leukapheresis (see below) and then loaded
ex vivo with tumour antigens. Then, they are intravenous-
administered into cancer patients to induce tumour-specific
effector T cells aimed at recognising and eliminating cancer
cells as well as inducing immunological memory to control
tumour growth [6, 8].
Adoptive cell transfer
This treatment is based on the intravenous infusion of
tumour-specific T cells. These cells can be isolated from
one of two sources: (i) autologous tumour-infiltrating
lymphocytes (TILs) from the tumour mass and (ii) au-
tologous T cells isolated from patient’s peripheral blood
(leukapheresis) that have been genetically modified to
express chimeric antigen receptors or specific anti-tumour
T cell receptors reactive to specific tumour-associated anti-
gens [11]. Exposition to high dose of interleukine-2 ex vivo
leads to their activation and expansion before being re-
infused to patients after lympho-depleting chemotherapy.
Autologous TIL therapy has been used for more than
10 years in melanoma patients and has resulted in dur-
able and in some cases complete response [9]. Regarding
solid tumours, TIL therapy is limited by the low avail-
ability and infiltration of TILs in tumour mass as well as
their exhaustion. Several studies are ongoing to improve
methods of ex vivo expansion and their reconditioning.
Chimeric antigen receptor T cell has already been con-
sidered as a breakthrough in haematological cancers,
with two drugs targeting antigen CD19, tisagenlecleucel
(Kymriah™) and axicabtagene ciloleucel (Yescarta™), that
were FDA-approved in 2018 for B cell lymphomas and
leukaemias [10, 11].
Despite looking very promising, these sophisticated ap-
proaches have severe toxicities that can be life-threatening
or fatal. These toxicities include the cytokine release syn-
drome, consisting of high fever and flu-like symptoms,
hypotension, and pulmonary fluid overload, as well as
neurotoxicity and capillary leak syndrome that require to
be managed under close observation. Therefore, this type
of treatment is administered only at certified centres.
Immune checkpoint inhibitors
ICIs are a new class of cancer immunotherapy drugs that
act as negative regulators of multiple immune check-
points, particularly in cytotoxic T cells, leading to inhib-
ition of T cell stimulation. The negative costimulatory
molecules such as CTLA-4, PD-1, T cell immunoglobu-
lin, and mucin domain-3 and lymphocyte-associated
gene 3 are expressed in different immune cell types,
including cytotoxic T cells, B cells, natural killer cells,
monocytes, tumour-associated macrophages, myeloid-
derived suppressor cells and dendritic cells exhibiting
immunosuppressive functions. As a result, T cells are
exhausted and the anti-cancer functions of the immune
system are weakened. ICIs remove these inhibitory
signals, restore T cells from their exhausted status, and
recover their cytotoxicity on tumour cells. Although res-
cue of exhausted T cells or depletion of regulatory T
cells is the primary function of ICIs, regulation of T cell
trafficking and migration have been also reported [12].
However, it was not until 2011 that the ICI ipilimumab
(Yervoy™), an anti-CTLA-4 monoclonal antibody, was
approved for metastatic melanoma, followed by the
development of other drugs such as PD-1 and PD-L1 in-
hibitors. Currently, seven ICIs are about to be FDA-
approved for a range of indications, in monotherapy or
in combination with other drugs. They consist of one
anti-CTLA-4 (ipilimumab (Yervoy®)), three anti-PD-1
(pembrolizumab (Keytruda®), nivolumab (Opdivo®), and
cemiplimab (Libtayo®)), and three anti-PD-L1 (atezolizu-
mab (Tecentriq®), durvalumab (Imfinzi®), and avelumab
(Bavencio®)) (Tables 1 and 2) [13].
How to assess response to treatment
Characteristics of response
Responses obtained after ICI immunotherapy are dif-
ferent from those observed after cytotoxic chemother-
apy. Although chemotherapy has a transient effect
with reduced tumour growth kinetic only during its
administration and re-growth after discontinuation,
immunotherapy may alter the biology of the patient
by inducing a memory cell response which includes
memory T cells that may provide long-term immune
protection [14–16].
Responses to immunotherapy have been described to
be more delayed with slower decrease of the total
tumour burden but with durable response even after
stopping the treatment [17, 18]. Although ICIs work
only in a subgroup or a minority of patients, they can in-
duce durable responses in 10–20% of treated patients,
even after the discontinuation of treatment, providing a
survival benefit [19, 20]. For example, for the first time
in melanoma history, ICIs induce long-lasting remission
exceeding 5 years [21].
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Moreover, two new forms of response patterns, so-called
pseudoprogressions, were observed initially in patients with
advanced melanoma treated with ipilimumab [17]:
– A response after an initial increase in total tumour
volume (Fig. 2)
– A reduction in total tumour burden after the
appearance of new lesions (Fig. 3)
Pseudoprogression does not reflect tumour cell growth
but may be misclassified as progressive disease. The
mechanism behind pseudoprogression could be related
Table 1 Clinical indications of the different immune checkpoint inhibitors
Immune checkpoint inhibitor Target Indications
Ipilimumab CTLA-4 Colorectal cancer, metastatic (microsatellite instability-high
or mismatch repair deficient in combination with nivolumab)
Melanoma, unresectable, or metastatic in combination with
nivolumab
Melanoma, adjuvant treatment
Advanced renal cell cancer, in combination with nivolumab
Pembrolizumab PD-1 Recurrent or metastatic cervical cancer
Advanced or metastatic gastric cancer
Head and neck cancer, squamous cell, unresectable/recurrent
or metastatic, alone or in combination with chemotherapy
Advanced hepatocellular carcinoma
Hodgkin lymphoma, classical, relapsed or refractory
Melanoma, adjuvant treatment
Melanoma, unresectable or metastatic
Merkel cell carcinoma, recurrent or metastatic
Microsatellite instability-high cancer, unresectable or metastatic
NSCLC, stage III or metastatic, single-agent therapy
NSCLC, metastatic, non-squamous, combination therapy with
chemotherapy
Primary mediastinal large B cell lymphoma, relapsed or refractory
Advanced renal cell carcinoma
Small cell lung cancer, metastatic
Urothelial carcinoma, locally advanced or metastatic
Nivolumab PD-1 Like pembrolizumab
Cemiplimab PD-1 Cutaneous squamous cell carcinoma, metastatic or locally advanced
Atezolizumab PD-L1 Breast cancer (triple-negative), locally advanced or metastatic in
combination with nab-paclitaxel
NSCLC, metastatic: first line with bevacizumab, paclitaxel,
and carboplatin
Previously-treated NSCLC: monotherapy
Small cell lung cancer, extensive-stage: first-line treatment with
carboplatin and etoposide
Urothelial carcinoma, locally advanced or metastatic
Durvalumab PD-L1 NSCLC (stage III), unresectable, initiated within 6 weeks after
chemo-radiotherapy
Urothelial carcinoma, locally advanced or metastatic
Avelumab PD-L1 Metastatic Merkel cell carcinoma
Advanced renal cell carcinoma, in combination with axitinib
Urothelial carcinoma, locally advanced or metastatic
CTLA4 Cytotoxic T-lymphocyte antigen 4, NSCLC Non-small cell lung cancer, PD-1 Programmed cell death protein 1, PD-L1 Programmed cell death protein ligand 1
Table 2 Rate of pseudoprogression in patients with melanoma or NSCLC
First author, year [reference] Number of patients Type of cancer Treatment Pseudoprogression (%)
Wolchock, 2009 [17] 227 Melanoma Ipilimumab 9.7
Hodi, 2016 [26] 327 Melanoma Pembrolizumab 7.0
Nishino, 2017 [24] 107 Melanoma Pembrolizumab 5.0
Gettinger, 2015 [84] 129 NSCLC Nivolumab 5.0
Nishino, 2017 [85] 160 NSCLC Nivolumab or pembrolizumab 0.6
Katz, 2018 [86] 166 NSCLC Anti-PD1 (nivolumab 80%) 2.0
Fujimoto, 2019 [27] 542 NSCLC Nivolumab 3.0
PD-1 Programmed cell death protein 1, NSCLC Non-small cell lung cancer
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to the infiltration of T cells into tumours, resulting ini-
tially in an apparent increase in tumour burden rather
than true proliferation of tumour cells [17]. Associated
inflammatory reaction, due to cytokine release, has been
also observed in on-treatment biopsy samples performed
after radiological progression in patients treated with ipi-
limumab [22]. Another explanation could be the time re-
quired to mount an adaptive immune response resulting
in a continued tumour growth until a sufficient response
develops [23].
Although pseudoprogression in patients treated with
ICIs has been hotly debated, its incidence is actually low
and differs depending on the tumour type (for example,
less frequent in non-small cell lung cancer patients
(< 5%) than in melanoma (< 10%)) (Table 2). As a
consequence, an increase of tumour burden during
ICI treatment is more likely to reflect true progres-
sion rather than pseudoprogression.
Pseudoprogression has been found to be more fre-
quent in younger patients, probably because of the better
reactivity of the immune system, and may occur at any
time after the onset of therapy [24]. Pseudoprogression
was mostly observed around 12 weeks, in particular in
melanoma patients treated with ipilimumab, although
more delayed pseudoprogression was also reported [25].
In melanoma patients, it has been shown that this
phenomenon can occur in lymph nodes, but more com-
monly in non-nodal locations such as the kidneys, liver,
lungs, peritoneum, adrenal glands, and chest and abdom-
inal walls [26]. Finally, patients experiencing a pseudopro-
gression have been shown to have a shorter duration
of response than patients with a typical response, but
a better chance of survival than patients with typical
progression [27].
Another atypical response after initiation of immuno-
therapy is the hyperprogression, i.e. a paradoxical accel-
eration of tumour growth kinetics. It has been described
after the onset of anti-PD1/PD-L1 therapy with an inci-
dence of about 10% [28] (Fig. 4). To avoid misdiagnosing
treatment-related disease hyperprogression with conven-
tional progressive disease, it has been suggested to use
the tumour growth rate to compare the growth rate
before and after the initiation of treatment [29]. Using a
definition of ≥ 2-fold increase of tumour growth rate
before and after anti-PD-1/PD-L1 therapy, a hyperpro-
gressive disease was found in 12 of 218 patients (9%)
[29]. No association was found between hyperprogres-
sion and baseline tumour burden, the type of the
Fig. 2 Comparison of RECIST 1.1 and iRECIST criteria for evaluation of a 45-year-old woman with metastatic melanoma treated with ipilimumab
(antiCTLA-4) and nivolumab (anti-PD-1). Baseline CT image (November 2017) shows a 13-mm lung metastasis (target lesion, upper panel, arrow)
and a 10-mm short-axis axillary lymph node (non-target lesion, lower panel, arrow). On a 3-month follow-up, both lesions enlarged with an
increase of 38% of the target lesion leading to a progressive disease (PD) and a stop of treatment according to RECIST 1.1 and an unconfirmed
PD with maintained treatment according to iRECIST criteria. On the two following CT examinations (March and June 2018), the lung metastasis
decreased in size, but the axillary lymph node was stable (unconfirmed PD) but still significantly enlarged compared to the baseline (still
unconfirmed PD according to iRECIST criteria). Finally, on August 2018, CT images showed a decrease in size of both lesions, confirming the
pseudoprogression with a response assessed to be -70%, leading to a partial response according to iRECIST criteria
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immunotherapy, tumour histology, and number of previ-
ous lines of treatment. Nevertheless, hyperprogression
was significantly correlated with patients’ age and de-
creased overall survival.
Notwithstanding these findings, the attribution of
hyperprogression to immunotherapy remains controver-
sial. In particular, hyperprogression has been observed in
patients having received other therapies, such as surgery,
radiotherapy, and/or chemotherapy or even in the ab-
sence of treatment [30, 31]. Moreover, the mechanisms
underlying hyperprogressive disease have not been eluci-
dated yet.
New criteria to assess the response to immunotherapy
Although relatively infrequent, these atypical response
patterns have important implications for patient man-
agement. To address the issue of pseudoprogression and
provide standardisation for assessing response to im-
munotherapy, new criteria have been developed. All
these criteria are based on two major statements: (1)
new lesions do not preclude progressive disease and (2)
a confirmation of progressive disease is required.
Immune-related response criteria (irRC) were devel-
oped for melanoma treated with ipilimumab and based
on modified World Health Organization criteria, which
use bi-dimensional tumour measurements (five lesions
per organ, up to ten visceral lesions and five cutaneous
index lesions) burden [17, 32]. The major differences
compared to the World Health Organization and
RECIST criteria were the incorporation of measurable
new lesions into the total tumour burden [2, 17] (Table
3). Moreover, response was allowed after an initial pro-
gression. Consequently, complete response is defined as
disappearance of all target lesions, partial response as a
≥ 50% reduction in the sum of target lesions, stable dis-
ease as neither sufficient shrinkage to qualify for partial
response nor sufficient increase to qualify for progressive
disease, and progressive disease as ≥ 25% increase of the
sum of target lesions plus new measurable lesion in
comparison with the disease nadir.
The immune-related response criteria using unidimen-
sional measurement, so-called irRECIST, has been devel-
oped based on RECIST 1.1 [2] adaptation of the irRC
[33]. These new criteria have been found to provide a
higher reproducibility compared to irRC, to be more
practical in clinical routine, and to provide response as-
sessment that can be directly compared to the results
from other clinical trials based on RECIST 1.1 criteria
[2]. Due to the unidimensional measurement, partial re-
sponse is now defined as ≥ 30% reduction in the sum of
Fig. 3 Pseudoprogression in a 65-year-old patient with lung carcinoma treated with nivolumab (anti-PD-1). Baseline axial CT showed a lung mass
in the upper right lobe with normal adrenal glands. At a 38-week follow-up (FU), there was a good reduction in the size of the lung mass, but a
new lesion appeared in the right adrenal gland (arrow). The patient was maintained under the same treatment. At 44-week follow-up, the right
adrenal mass disappeared, confirming the diagnosis of pseudoprogression
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target lesions, stable disease as sum of target le-
sions < 20% increase and < 30% reduction, and a
progressive disease as ≥ 20% increase of the sum of
target lesions plus new measurable lesions from the
nadir.
More recently, the RECIST working group published
the modified RECIST 1.1 for immune-based therapy, so-
called immune-related RECIST (irRECIST) [34]. Also
using RECIST 1.1-based measurement, irRECIST intro-
duced the new concept of “unconfirmed progressive dis-
ease” corresponding to progressive disease that remains
to be confirmed on a 4–8-week follow-up imaging. If the
patient condition is classified as unconfirmed progressive
disease and is clinically stable, treatment should be con-
tinued. As opposed to other criteria developed for im-
munotherapy, a non-target lesion progression can define
a progressive disease. Following irRECIST criteria, a par-
tial response is defined as a ≥ 30% reduction in the sum
of target lesions and unconfirmed progressive disease as
≥ 20% increase in the sum of target lesions from the
nadir or non-target lesion progression or appearance of
new lesion.
The progressive disease is confirmed in case of:
– Target lesions previously classified as unconfirmed
progressive disease and presence of an increase in
tumour burden of target lesions ≥ 5 mm on the 4–8-
week follow-up imaging;
– Or non-target lesion previously classified as
unconfirmed progressive disease and significant
increase of non-target lesion on the 4–8-week
follow-up imaging;
– Or new lesions resulting of UPD and increase of
tumour burden ≥ 5 mm of these new lesions or
increase in the number of new lesions on the 4–8-
week follow-up imaging.
For progression-free survival assessment, the date
used for progressive disease is the first unconfirmed
progressive disease date, if the latter is subsequently
confirmed.
Finally, the immune-modified RECIST (imRECIST) cri-
teria were developed initially for implementation of atezo-
lizumab studies [35]. These criteria include key principles
of irRC applied with unidimentional RECIST 1.1 criteria,
similarly to irRECIST criteria and share the same defin-
ition of response and progression as the irRECIST.
Table 3 Comparison of the different criteria developed for the assessment of response to immunotherapy
Criteria, year [reference] irRC, 2009 [17] irRECIST, 2013 [33] iRECIST, 2017 [34] imRECIST, 2018 [35]
Baseline
Definition of target lesion World Health Organization
criteria +5 cutaneous targets
RECIST 1.1 RECIST 1.1 RECIST 1.1
Definition of
non-target lesion
Not specified RECIST 1.1 RECIST 1.1 RECIST 1.1
Definition of lymph node Not specified RECIST 1.1 RECIST 1.1 RECIST 1.1
Follow-up
New lesion ≥ 5 × 5mm; up to 5/organ;
5 new cutaneous and 10
visceral lesions
PD not defined
Measurement of new lesions











Non-target lesion Only to define irCR Only to define irCR RECIST 1.1
May define UPD
Only to define irCR
PD definition Determined only on
measurable disease (≥ 25%
increase in the sum of target
lesions and new lesions from
the nadir)
Negated by subsequent
non-PD assessment ≥ 4 weeks
Determined only on
measurable disease
(≥ 20% increase in the
sum of target lesions





Confirmed PD if :
- Unconfirmed PD of target
lesions on previous exam
and increase in tumour
burden of target lesions
≥ 5 mm
- Unconfirmed PD of
non-target lesions and their
significant increase
- Unconfirmed PD
for new lesions and increase
in tumour burden ≥ 5 mm or




(≥ 20% increase in the
sum of target lesion
and new lesions from
the nadir)
The presence of new




irRC Immune-related response criteria, imRECIST Immune-modified RECIST, PD Progressive disease
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The differences between these criteria are summarised
in Table 3. In clinical trials, irRECIST and imRECIST
are the most promising criteria to assess response rate
and progression-free survival that are the most com-
monly used surrogate endpoints to assess overall survival
[36]. However, data are still limited, in particular in
other types of cancers than melanoma and non-small
cell lung cancer, to draw any definitive conclusion. Ac-
cordingly, these criteria, developed for clinical trial,
should be used with caution in clinical routine.
Immune-related adverse events: the role of imaging
Although ICIs are safer compared to cytotoxic chemo-
therapy, they enhance the immune activity and may
cause a dysregulation of immune homeostasis in normal
tissues, which may lead to specific toxicities called “im-
mune-related adverse events” (irAEs). They generally
start the first few weeks after treatment; nevertheless,
they can occur at any time, even after treatment discon-
tinuation [37–39]. Their incidence and severity depend
on the agent, with higher all-grade rates reported with
anti-CTLA4 (up to 80%) compared to anti-PD1 (27%)
and anti-PDL1 (17%) [39–42]. Different tissues and or-
gans may be affected and multisystem toxicities are
common, with a spectrum of imaging manifestations in
each organ [43]. Fatigue, cutaneous toxicities, colitis, and
endocrine dysfunctions are the most frequent events,
followed by hepatitis and pneumonitis [39–42]. Other
rare irAEs include nephrologic, neurologic, cardiologic,
and haematologic toxicities [37, 40–42]. Although they
are generally manageable mild toxicities, severe and life-
threatening events may occur in up to 7%, 3%, and 30%
of patients receiving anti-PD1, anti-PDL1, and anti-
CTLA4, respectively, reaching up to 55% with combined
immunotherapy [39–42]. IrAEs generally respond to im-
munotherapy holding and require corticosteroids and
immunosuppressive treatment in more severe cases
along with organ-specific treatment. Radiologic manifes-
tations of irAEs can be found in up to 17% of patients
receiving immunotherapy, and this may precede clinical
manifestations [44–48]. The knowledge of these peculiar
toxicities is of utmost importance, because it ensures
their early recognition while requiring the exclusion of
differentials, mainly of infectious or tumoural nature.
Gastrointestinal, liver, and pancreatic toxicities
Colitis is one of the most frequent and potentially severe
irAEs induced by anti-CTLA4 [38, 39]. Diarrhoea is re-
ported in up to 50% of patients; other presenting symp-
toms include abdominal pain, bloody stools, and fever
[49]. Complications include perforation, sepsis, frank
bleeding, or dehydration [49]. At computed tomography
(CT), ICI-induced colitis appears as a diffuse inflamma-
tory pattern characterised by wall thickening, mucosal
hyperenhancement, mesenteric hyperaemia, and air-fluid
levels [47, 50, 51]. Segmental involvement has also been
Fig. 4 Paradoxical acceleration of tumour growth kinetics in a patient with metastatic melanoma treated with ipilimumab and nivolumab.
Baseline axial CT image and corresponding 18F-FDG PET/CT image show few perisplenic peritoneal metastatic implants. Two months after the
initiation of immunotherapy, both imaging modalities show a dramatic increase in peritoneal metastases.
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reported. At positron emission tomography (PET)/CT, col-
itis results in diffuse and intense 18F-fluorodeoxyglucose
(18F-FDG)-avidity along the entire bowel [47, 50] (Fig. 5).
These features may precede the onset of symptoms. Colon-
oscopy may show erythaema, ulceration, and mucosal fri-
ability, whereas neutrophilic, lymphocytic, or eosinophilic
intraepithelial infiltrates and crypt invasion can be found on
pathologic specimens [49, 50].
ICI-related hepatitis has been reported in up to 19% of
patients receiving anti-CTLA4, whereas it is rarely re-
ported when using anti-PD1 or anti-PDL1 [40, 42].
Although it is usually limited to a mild elevation of
transaminases, life-threatening liver dysfunction may
occur [38, 39]. Imaging findings are shared with other
causes of acute liver dysfunction, ranging from the ab-
sence of detectable abnormalities to hepatomegaly with
parenchymal heterogeneity, periportal oedema, and peri-
hepatic ascites [47, 50, 51]. While physiological 18F-FDG
uptake is usually not affected by diffuse liver diseases, a
case of ICI-induced hepatitis showing an intense liver
18F-FDG-uptake area at PET/CT has been reported [52].
The pancreas is rarely affected by irAEs, resulting in
elevation of amylase and lipase or hyperglycaemia and
diabetes [38, 39, 41]. Symptomatic pancreatitis is very
Fig. 5 18F-FDG PET/CT image of a stage IV enterocolitis during anti-CTLA-4 treatment in a patient with metastatic melanoma. Immunotherapy
was interrupted, and a high-dose steroid therapy was started
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rare. Classic features of acute pancreatitis including en-
largement and oedema of the pancreatic gland associated
with peripancreatic oedema and fluid collections can be
observed [50]. Diffuse pancreatic FDG uptake on positron
emission tomography/CT has been reported [53].
Endocrine toxicities
Hypophysitis may develop during anti-CTLA4 treatment
in up to 13% of patients, whereas it is rarely associated
with anti-PD1 and anti-PDL1 ICI treatments [39]. Clin-
ical and radiological features are similar to lymphocytic
hypophysitis. Fatigue, headache, and hypopituitarism-
related symptoms are often reported. Hypophysitis can
incidentally be detected by imaging in asymptomatic
patients or before onset of symptoms. It presents as an
enlarged hypophysis on brain CT or magnetic resonance
imaging (MRI), or an 18F-FDG-avid pituitary gland on
PET/CT [46, 54, 55]. Any suspected hypophysitis re-
quires an MRI of the pituitary gland to confirm the diag-
nosis and exclude mimickers such as metastasis and
pituitary adenoma. On MRI, the pituitary gland is en-
larged without mass effect on the optic chiasma, with a
thickening of the infundibulum, and the hyperintensity of
the posterior part of the gland is often missing [56, 57].
There is also a homogeneous or heterogeneous en-
hancement of the pituitary gland on contrast-enhanced
images [56, 57].
Generally asymptomatic, ICI-induced thyroid dysfunc-
tion often presents as mild hypothyroidism or hyperthy-
roidism on blood tests, with detectable anti-thyroid
peroxidase and anti-thyroglobulin antibodies in most
cases [58]. It is more frequently reported in patients re-
ceiving combined immunotherapy (20%) than in those
with anti-PD1/antiPD-L1 (up to 10%) or anti-CTLA4
(around 5%) monotherapy [38, 39]. Ultrasound is the
tool of choice in this setting. Thyroid enlargement with
heterogeneous and hypoechoic parenchyma, often with a
nodular or pseudonodular pattern, may be observed
[55]. An increased vascularity at colour-Doppler evalu-
ation may be also found. Nevertheless, it may be inci-
dentally detected as diffuse hypermetabolic thyroid
gland at restaging 18F-FDG PET/CT [47, 55].
Rarely, primary or secondary adrenalitis may occur
during immunotherapy, leading to adrenal insufficiency
[38, 39]. The adrenal glands show bilateral enlargement
at conventional imaging and bilateral mild 18F-FDG-
avidity on PET/CT [55, 59].
Thoracic and cardiac toxicities
Pneumonitis is an autoimmune toxicity with a wide
range of clinical course, ranging from mild dyspnoea to
life-threatening respiratory failure [60], with up to 2% of
patients developing severe pneumonitis [38]. Unlike the
majority of irAEs, it is less common with anti-CTLA-4
monotherapy than with anti-PD-1 treatment [38, 60]. It
occurs in up to 5% of patients receiving anti-PD1 and
anti-PDL1, while it arises in 10% of patients receiving
combination treatment [38, 60, 61], with higher odds of
pneumonitis in non-small cell lung cancer compared with
melanoma [61–63]. It is noteworthy that after pneumon-
itis resolution, some patients may be able to restart PD-1
inhibitor therapy without experiencing recurrent pneu-
monitis. Nevertheless, recurrence may occur in this set-
ting, and pneumonitis flare corresponding to a recurrence
of the pneumonitis after the completion of a corticoster-
oid taper without restarting ICIs or any other systemic
agents have also been described in some cases [64].
The spectrum of imaging aspects varies between minor
interstitial anomalies up to acute interstitial pneumonia or
acute respiratory distress syndrome pattern, these aspects
reflecting pneumonitis grades [64]. It includes patterns of
organising pneumonia, the most commonly seen, hypersen-
sitivity pneumonitis, non-specific interstitial pneumonitis, or
non-specified pneumonitis [64, 65]. Major elementary le-
sions are ground-glass opacities with a variable extent and
location, reticulations, and alveolar consolidations, typically
with a subpleural and peribronchovascular distribution in
organising pneumonia pattern [61] (Fig. 6). Progression of
an organising pneumonia pattern to a non-specific ground-
glass opacity has been described. In addition, nodular aspect
mimicking a tumour recurrence, as well as pembrolizumab-
associated bronchiolitis, pleural effusions, or tracheitis, may
be observed [45]. The diagnosis may be sensitive in case of
Fig. 6 Immune-related pneumonitis presenting as an organising
pneumonia pattern in a patient with metastatic lung cancer that
occurred after 13 cycles of anti-PD1 therapy. This axial CT image in
lung windowing shows multifocal alveolar consolidations in a
subpleural and peribronchovascular location, predominating at the
level of the left upper lobe. Although suggestive of a diagnosis of
organising pneumonia, infectious or tumoural lesions were excluded
by means of a brochoalveolar lavage. Note that numerous round
lucencies are visible within the alveolar consolidations,
corresponding to associated centrilobular emphysema in this heavy
smoker patient
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underlying disease such as chronic obstructive pulmonary
disease or previous radiotherapy. Moreover, if imaging
appearances may suggest the diagnosis of immune-related
pneumonitis, the establishment of the final diagnosis may
remain challenging. The differential diagnosis must always
be kept in mind, especially infectious disorders or tumour
recurrence, this requiring a bronchoalveolar lavage in nu-
merous cases of lung parenchymatous changes, if enabled
by patient’s conditions.
Sarcoid-like reactions, including lymphadenopathy and
pulmonary granulomatosis, have been reported in up to
5–7% of patients treated with ICIs [43, 47]. Typical
imaging findings are symmetric mediastinal and hilar
lymph node enlargement, which may appear hypermeta-
bolic on PET/CT (Fig. 7). Micronodules with perilymph-
atic distribution, especially in subpleural location, may
also be seen [66].
Rarely, ICIs may lead to cardiac toxicity, including myo-
carditis, arrhythmias, Takotsubo cardiomyopathy, and
pericarditis. The incidence of myocarditis range from 0.1
to 1%, and a fulminant course is common with fatal case
rates of 25–50% of them [38, 39]. Most cases occur shortly
after initiation of ICI therapy. Symptoms may vary, ran-
ging from sudden onset of shortness of breath, chest pain,
to heart failure. Importantly, a normal electrocardiogram,
biomarkers, or a preserved left ventricular function do not
rule out ICI-associated myocarditis. There is an undeni-
able role of cardiac MRI that can show characteristic find-
ings of acute myocarditis, including myocardial oedema
and late gadolinium enhancement in the focal subepicar-
dial lateral wall [67, 68]. Cases of pericarditis, sometimes
fatal, have also been reported [69].
Other toxicities
While arthralgias, myalgia, and inflammatory arthritis fre-
quently occur as irAEs, vasculitis is an uncommon presen-
tation, involving large vessels, nervous system, and less
commonly medium and small vessels [70]. ICI-associated
myositis with or without myasthenia gravis are the more
frequent neuromuscular complications [71].
Fig. 7 Sarcoid-like reactions in a patient with metastatic melanoma treated with ipilimumab (antiCTLA-4) and nivolumab (anti-PD-1). Twelve-week
follow-up (FU) 18F-FDG PET/CT images show typical hypermetabolic symmetric mediastinal and hilar lymph node enlargement, very suggestive of
a sarcoid-like reaction. These features disappeared on the following 18F-FDG-PET/CT images at 18-week FU, confirming the diagnosis of sarcoid-
like reaction under immunotherapy
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How to predict response to immunotherapy
Remarkable responses to immunotherapies are currently
limited to a minority of patients and indications. This
highlights the need to identify more effective biomarkers
that can be used in clinical routine, not only for an ap-
propriate patient selection but also to offer personalised
therapy.
The most extensively studied biomarker is the PD-L1
status. For example, in patients with newly diagnosed
advanced non-small cell lung cancers and ≥ 50% PD-L1
expression, the combination of chemotherapy plus anti-
PD-1 treatment with pembrolizumab significantly im-
proved their objective response rate, progression-free
survival, and overall survival [72]. However, its clinical
use has been hampered by its dynamic expression that
changes in relation to local cytokines and other factors.
Thus, the threshold that separates a positive from nega-
tive PD-L1 expression remains debated and varies for
each tumour type. Based on this experience, at present,
no patient with advanced cancer and an established clin-
ical rationale for the use of ICIs should be refused on
the basis of lack of PD-L1 expression.
The rate of somatic mutations in tumour, the so-
called tumour mutational burden (TMB), has also shown
a potential response to ICIs. Mutated proteins can be
recognised as non-self neo-antigens more easily by the
adaptive immune system. In this context, ICIs are more
effective. However, the TMB cutoff that could predict a
response to ICI for each tumour type has shown to be
variable [73]. No association was found between high
TMB and survival in patients not treated with ICI,
underlying the predictive value of high TMB for ICI
therapies [74].
The mismatch repair proteins play a crucial role in the
repair of DNA sequence mismatches during replication.
A defective mismatch repair system leads to errors in
DNA replication that accumulate in microsatellites,
resulting in microsatellite instability. These defects are a
result of either a germline mutation in the mismatch
repair gene (Lynch syndrome) or more commonly as
epigenetic inactivation of them. Tumours that are classi-
fied to have high microsatellite instability also have an
accumulation of somatic mutations, resulting in a higher
neoantigen load, which promotes activation and recruit-
ment of T cells and hence sensitivity to immunotherapy
[75] (Fig. 8). Currently, the National Comprehensive
Cancer Network guidelines encourage microsatellite
instability testing for all patients with advanced gastro-
intestinal cancer, and for this population, ICIs are FDA-
approved. Microsatellite instability is highly variable
among cancers, being most common in gastric and colo-
rectal cancers (11.1%), whereas other tumour types such
as pancreatic cancer are low [76].
Tumour infiltrating lymphocytes correspond to lympho-
cytes that directly oppose or surround tumour cells. The
percentage degree of TILs has been shown to correlate
with a favourable prognosis in several tumours including
melanoma and breast and ovarian cancers [77, 78]. The
degree of TILs may be defined by both the extent and
density of the TILs using an “immunoscore” based on the
numeration of CD3+ and CD8+ T cell at the intratu-
moural region as well as at the invasive margin area [79].
Finally, three different immune profiles have been de-
scribed: (1) the immune inflamed with dense CD8+ T cell
infiltration within the tumour (highest probability of re-
sponse), (2) the immune-excluded with abundant immune
cells around the tumour but not penetrating inside the
tumour (intermediate probability of response), and (3) the
immune desert with few or no CD8+ T cells (lowest prob-
ability of response to immunotherapy).
Fig. 8 A 75-year-old woman with a low-differentiated primary cardiac sarcoma with microsatellite instability, treated with pembrolizumab (anti-
PD-1). Baseline contrast-enhanced MRI image shows a large retroatrial mass (arrow). Two months follow-up (FU) imaging shows a good reduction
in the size of the mass assessed as -34% according to iRECIST criteria (partial response, arrow). One year FU imaging shows a complete response
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Only few imaging biomarkers have been studied for pre-
dicting response to immunotherapy. A radiomics ap-
proach was used to assess tumour-infiltrating CD8+ T
cells in patients included in phase 1 trials of PD-1 and
PD-L1 monotherapy [80]. A radiomic signature of CD8+
T cells was developed using CT images and RNA sequen-
cing data from 135 patients (training set) and validated on
three different cohorts of patients including 137 patients
treated with anti-PD-1 and anti-PD-L1 drugs. High base-
line radiomics score was associated with higher proportion
of patients with objective response at 3 and 6months.
Moreover, high radiomics score was significantly associ-
ated with improved outcomes with a median overall sur-
vival of 24.3 versus 11.5months in high and low radiomics
score, respectively.
Molecular imaging techniques using radioactive tracers
that target PD-1 and PD-L1 have also been explored in a
preclinical study [81, 82]. A first-in-human study using
PET with 89Zr-labeled atezolizumab has been conducted
in 22 patients to predict response to PD-L1 treatment
[83]. The authors showed a significant correlation between
89Zr-labeled atezolizumab uptake and patient outcomes in
terms of progression-free and overall survival. Interest-
ingly, responses were better correlated with baseline PET
tracer fixation than with PD-L1 status using immunohis-
tochemistry or RNA sequencing of post-tracer biopsies.
In this context, the potential applicability of these bio-
markers in different disease settings is still pending with
probably the exception of first-line lung cancer for PD-
L1 expression.
Conclusions
Cancer immunotherapy is becoming, in a few years, one
of the most promising treatments of wide types of cancers.
Currently, immunotherapy benefits only to some patients,
and selecting patients who will benefit from immunother-
apy is one of the major future challenges. Familiarity with
the specificity of response and immune-related side effects
is essential for radiologists to accurately evaluate the re-
sponse to treatment and help clinician for optimal patient
management. Although pseudoprogression occurs only in
few patients treated with ICIs, new criteria (irRC, irRE-
CIST, iRECIST, and imRECIST) has been developed to
address this issue in clinical trials. Their use in clinical
routine should be prudent as data are still limited. More-
over, new image interpretation challenges will probably
occur in the future with the increasing use of combined
therapies with conventional chemotherapy and locoregio-
nal therapies (radiotherapy, cryotherapy, etc.) as well as
other types of immunotherapy such as vaccines or adop-
tive cell transfer therapy.
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